Patients  ||| S:0 E:9 ||| NNS
with  ||| S:9 E:14 ||| IN
isolated  ||| S:14 E:23 ||| VBN
prolonged  ||| S:23 E:33 ||| VBN
in  ||| S:33 E:36 ||| IN
vitro  ||| S:36 E:42 ||| JJ
bleeding  ||| S:42 E:51 ||| NN
time ||| S:51 E:55 ||| NN
.  ||| S:55 E:57 ||| .
Clinical  ||| S:57 E:66 ||| JJ
symptoms  ||| S:66 E:75 ||| NNS
In  ||| S:75 E:78 ||| IN
patients  ||| S:78 E:87 ||| NNS
with  ||| S:87 E:92 ||| IN
isolated  ||| S:92 E:101 ||| VBN
prolonged  ||| S:101 E:111 ||| VBN
in  ||| S:111 E:114 ||| IN
vitro  ||| S:114 E:120 ||| JJ
bleeding  ||| S:120 E:129 ||| NN
time  ||| S:129 E:134 ||| NN
there  ||| S:134 E:140 ||| EX
is  ||| S:140 E:143 ||| VBZ
no  ||| S:143 E:146 ||| DT
standardised  ||| S:146 E:159 ||| JJ
treatment  ||| S:159 E:169 ||| NN
concept ||| S:169 E:176 ||| NN
.  ||| S:176 E:178 ||| .
With  ||| S:178 E:183 ||| IN
this  ||| S:183 E:188 ||| DT
study  ||| S:188 E:194 ||| NN
we  ||| S:194 E:197 ||| PRP
characterized  ||| S:197 E:211 ||| VBD
the  ||| S:211 E:215 ||| DT
extent  ||| S:215 E:222 ||| NN
of  ||| S:222 E:225 ||| IN
bleeding  ||| S:225 E:234 ||| VBG
symptoms ||| S:234 E:242 ||| NNS
.  ||| S:242 E:244 ||| .
All  ||| S:244 E:248 ||| DT
diagnoses  ||| S:248 E:258 ||| NN
known  ||| S:258 E:264 ||| VBN
to  ||| S:264 E:267 ||| TO
cause  ||| S:267 E:273 ||| VB
prolonged  ||| S:273 E:283 ||| VBN
in  ||| S:283 E:286 ||| IN
vitro  ||| S:286 E:292 ||| JJ
bleeding  ||| S:292 E:301 ||| NN
time  ||| S:301 E:306 ||| NN
( ||| S:306 E:307 ||| -LRB-
PFA-100 ||| S:307 E:314 ||| NNP
)  ||| S:314 E:316 ||| -RRB-
( ||| S:316 E:317 ||| -LRB-
epinephrine-cartridge  ||| S:317 E:339 ||| NNP
> ||| S:339 E:340 ||| CD
160  ||| S:340 E:344 ||| CD
s ||| S:344 E:345 ||| NN
,  ||| S:345 E:347 ||| ,
ADP-cartridge  ||| S:347 E:361 ||| JJ
>  ||| S:361 E:363 ||| CD
120  ||| S:363 E:367 ||| CD
s ||| S:367 E:368 ||| CD
)  ||| S:368 E:370 ||| -RRB-
have  ||| S:370 E:375 ||| VBP
been  ||| S:375 E:380 ||| VBN
excluded ||| S:380 E:388 ||| VBN
,  ||| S:388 E:390 ||| ,
such  ||| S:390 E:395 ||| JJ
as  ||| S:395 E:398 ||| IN
platelet  ||| S:398 E:407 ||| JJ
function  ||| S:407 E:416 ||| NN
disorders ||| S:416 E:425 ||| NNS
,  ||| S:425 E:427 ||| ,
effects  ||| S:427 E:435 ||| NNS
of  ||| S:435 E:438 ||| IN
medications ||| S:438 E:449 ||| NN
,  ||| S:449 E:451 ||| ,
nutrition  ||| S:451 E:461 ||| NN
or  ||| S:461 E:464 ||| CC
von  ||| S:464 E:468 ||| NNP
Willebrand  ||| S:468 E:479 ||| NNP
disease.  ||| S:479 E:488 ||| CD
75  ||| S:488 E:491 ||| CD
patients  ||| S:491 E:500 ||| NNS
( ||| S:500 E:501 ||| -LRB-
77 ||| S:501 E:503 ||| CD
% ||| S:503 E:504 ||| NN
,  ||| S:504 E:506 ||| ,
n  ||| S:506 E:508 ||| VBG
=  ||| S:508 E:510 ||| SYM
58  ||| S:510 E:513 ||| CD
women ||| S:513 E:518 ||| NNS
;  ||| S:518 E:520 ||| :
23 ||| S:520 E:522 ||| CD
% ||| S:522 E:523 ||| NN
,  ||| S:523 E:525 ||| ,
n  ||| S:525 E:527 ||| VBG
=  ||| S:527 E:529 ||| SYM
17  ||| S:529 E:532 ||| CD
men ||| S:532 E:535 ||| NNS
,  ||| S:535 E:537 ||| ,
median  ||| S:537 E:544 ||| JJ
age  ||| S:544 E:548 ||| NN
46  ||| S:548 E:551 ||| CD
( ||| S:551 E:552 ||| -LRB-
16-81 ||| S:552 E:557 ||| NNP
)  ||| S:557 E:559 ||| -RRB-
years  ||| S:559 E:565 ||| NNS
were  ||| S:565 E:570 ||| VBD
included ||| S:570 E:578 ||| VBN
.  ||| S:578 E:580 ||| .
All  ||| S:580 E:584 ||| DT
bleeding  ||| S:584 E:593 ||| JJ
symptoms  ||| S:593 E:602 ||| NNS
have  ||| S:602 E:607 ||| VBP
been  ||| S:607 E:612 ||| VBN
stored  ||| S:612 E:619 ||| VBN
in  ||| S:619 E:622 ||| IN
a  ||| S:622 E:624 ||| DT
databank  ||| S:624 E:633 ||| NN
with  ||| S:633 E:638 ||| IN
help  ||| S:638 E:643 ||| NN
of  ||| S:643 E:646 ||| IN
a  ||| S:646 E:648 ||| DT
comprehensive  ||| S:648 E:662 ||| JJ
questionnaire.  ||| S:662 E:677 ||| CD
78 ||| S:677 E:679 ||| CD
%  ||| S:679 E:681 ||| NN
( ||| S:681 E:682 ||| -LRB-
n  ||| S:682 E:684 ||| CD
=  ||| S:684 E:686 ||| SYM
54 ||| S:686 E:688 ||| CD
)  ||| S:688 E:690 ||| -RRB-
of  ||| S:690 E:693 ||| IN
all  ||| S:693 E:697 ||| DT
patients  ||| S:697 E:706 ||| NNS
reported  ||| S:706 E:715 ||| VBD
of  ||| S:715 E:718 ||| IN
having  ||| S:718 E:725 ||| VBG
had  ||| S:725 E:729 ||| VBD
an  ||| S:729 E:732 ||| DT
operation ||| S:732 E:741 ||| NN
,  ||| S:741 E:743 ||| ,
69.8 ||| S:743 E:747 ||| CD
%  ||| S:747 E:749 ||| NN
( ||| S:749 E:750 ||| -LRB-
n  ||| S:750 E:752 ||| CD
=  ||| S:752 E:754 ||| SYM
37 ||| S:754 E:756 ||| CD
)  ||| S:756 E:758 ||| -RRB-
of  ||| S:758 E:761 ||| IN
them  ||| S:761 E:766 ||| PRP
described  ||| S:766 E:776 ||| VBD
postoperative  ||| S:776 E:790 ||| JJ
bleedings  ||| S:790 E:800 ||| NNS
( ||| S:800 E:801 ||| -LRB-
p  ||| S:801 E:803 ||| CD
=  ||| S:803 E:805 ||| SYM
0.0373 ||| S:805 E:811 ||| CD
) ||| S:811 E:812 ||| -RRB-
.  ||| S:812 E:814 ||| .
13.5 ||| S:814 E:818 ||| CD
%  ||| S:818 E:820 ||| NN
( ||| S:820 E:821 ||| -LRB-
n  ||| S:821 E:823 ||| CD
=  ||| S:823 E:825 ||| SYM
5 ||| S:825 E:826 ||| CD
)  ||| S:826 E:828 ||| -RRB-
of  ||| S:828 E:831 ||| IN
the  ||| S:831 E:835 ||| DT
54  ||| S:835 E:838 ||| CD
could  ||| S:838 E:844 ||| MD
remember  ||| S:844 E:853 ||| VB
having  ||| S:853 E:860 ||| VBG
been  ||| S:860 E:865 ||| VBN
randomly  ||| S:865 E:874 ||| RB
treated  ||| S:874 E:882 ||| VBN
by  ||| S:882 E:885 ||| IN
the  ||| S:885 E:889 ||| DT
administration  ||| S:889 E:904 ||| NN
of  ||| S:904 E:907 ||| IN
a  ||| S:907 E:909 ||| DT
transfusion  ||| S:909 E:921 ||| NN
and  ||| S:921 E:925 ||| CC
only  ||| S:925 E:930 ||| RB
2.7 ||| S:930 E:933 ||| CD
%  ||| S:933 E:935 ||| NN
( ||| S:935 E:936 ||| -LRB-
n  ||| S:936 E:938 ||| CD
=  ||| S:938 E:940 ||| SYM
1 ||| S:940 E:941 ||| CD
)  ||| S:941 E:943 ||| -RRB-
were  ||| S:943 E:948 ||| VBD
treated  ||| S:948 E:956 ||| VBN
by  ||| S:956 E:959 ||| IN
substitution  ||| S:959 E:972 ||| NN
of  ||| S:972 E:975 ||| IN
von  ||| S:975 E:979 ||| NNP
Willebrand  ||| S:979 E:990 ||| NNP
factor.  ||| S:990 E:998 ||| CD
71 ||| S:998 E:1000 ||| CD
%  ||| S:1000 E:1002 ||| NN
( ||| S:1002 E:1003 ||| -LRB-
n  ||| S:1003 E:1005 ||| CD
=  ||| S:1005 E:1007 ||| SYM
51 ||| S:1007 E:1009 ||| CD
)  ||| S:1009 E:1011 ||| -RRB-
patients  ||| S:1011 E:1020 ||| NNS
indicated  ||| S:1020 E:1030 ||| VBD
haematoma  ||| S:1030 E:1040 ||| NNS
( ||| S:1040 E:1041 ||| -LRB-
p  ||| S:1041 E:1043 ||| CD
=  ||| S:1043 E:1045 ||| SYM
0.8116 ||| S:1045 E:1051 ||| CD
) ||| S:1051 E:1052 ||| -RRB-
.  ||| S:1052 E:1054 ||| .
About  ||| S:1054 E:1060 ||| IN
33.8 ||| S:1060 E:1064 ||| CD
%  ||| S:1064 E:1066 ||| NN
( ||| S:1066 E:1067 ||| -LRB-
n  ||| S:1067 E:1069 ||| CD
=  ||| S:1069 E:1071 ||| SYM
24 ||| S:1071 E:1073 ||| CD
)  ||| S:1073 E:1075 ||| -RRB-
patients  ||| S:1075 E:1084 ||| NNS
had  ||| S:1084 E:1088 ||| VBD
gum  ||| S:1088 E:1092 ||| JJ
bleeding  ||| S:1092 E:1101 ||| NN
and  ||| S:1101 E:1105 ||| CC
40.8 ||| S:1105 E:1109 ||| CD
%  ||| S:1109 E:1111 ||| NN
( ||| S:1111 E:1112 ||| -LRB-
n  ||| S:1112 E:1114 ||| CD
=  ||| S:1114 E:1116 ||| SYM
29 ||| S:1116 E:1118 ||| CD
,  ||| S:1118 E:1120 ||| ,
p  ||| S:1120 E:1122 ||| VBG
=  ||| S:1122 E:1124 ||| SYM
0.7808 ||| S:1124 E:1130 ||| CD
)  ||| S:1130 E:1132 ||| -RRB-
patients  ||| S:1132 E:1141 ||| NNS
reported  ||| S:1141 E:1150 ||| VBD
bleeding  ||| S:1150 E:1159 ||| VBG
after  ||| S:1159 E:1165 ||| IN
the  ||| S:1165 E:1169 ||| DT
dentist.  ||| S:1169 E:1178 ||| CD
41.4 ||| S:1178 E:1182 ||| CD
%  ||| S:1182 E:1184 ||| NN
( ||| S:1184 E:1185 ||| -LRB-
n  ||| S:1185 E:1187 ||| CD
=  ||| S:1187 E:1189 ||| SYM
29 ||| S:1189 E:1191 ||| CD
)  ||| S:1191 E:1193 ||| -RRB-
patients  ||| S:1193 E:1202 ||| NNS
suffered  ||| S:1202 E:1211 ||| VBD
under  ||| S:1211 E:1217 ||| IN
frequent  ||| S:1217 E:1226 ||| JJ
epistaxis  ||| S:1226 E:1236 ||| NNS
( ||| S:1236 E:1237 ||| -LRB-
p  ||| S:1237 E:1239 ||| CD
=  ||| S:1239 E:1241 ||| SYM
0.0212 ||| S:1241 E:1247 ||| CD
) ||| S:1247 E:1248 ||| -RRB-
.  ||| S:1248 E:1250 ||| .
There  ||| S:1250 E:1256 ||| EX
was  ||| S:1256 E:1260 ||| VBD
no  ||| S:1260 E:1263 ||| DT
correlation  ||| S:1263 E:1275 ||| NN
between  ||| S:1275 E:1283 ||| IN
prolonged  ||| S:1283 E:1293 ||| JJ
epinephrine  ||| S:1293 E:1305 ||| NNS
bleeding  ||| S:1305 E:1314 ||| VBG
time  ||| S:1314 E:1319 ||| NN
to  ||| S:1319 E:1322 ||| TO
VWF ||| S:1322 E:1325 ||| NNP
: ||| S:1325 E:1326 ||| :
Ag  ||| S:1326 E:1329 ||| NNP
( ||| S:1329 E:1330 ||| -LRB-
rho  ||| S:1330 E:1334 ||| CD
=  ||| S:1334 E:1336 ||| SYM
0.16 ||| S:1336 E:1340 ||| CD
)  ||| S:1340 E:1342 ||| -RRB-
nor  ||| S:1342 E:1346 ||| CC
to  ||| S:1346 E:1349 ||| TO
VWF ||| S:1349 E:1352 ||| NNP
: ||| S:1352 E:1353 ||| :
RCo  ||| S:1353 E:1357 ||| NNP
( ||| S:1357 E:1358 ||| -LRB-
rho  ||| S:1358 E:1362 ||| CD
=  ||| S:1362 E:1364 ||| SYM
0.12 ||| S:1364 E:1368 ||| CD
)  ||| S:1368 E:1370 ||| -RRB-
nor  ||| S:1370 E:1374 ||| CC
between  ||| S:1374 E:1382 ||| IN
prolonged  ||| S:1382 E:1392 ||| JJ
epinephrine  ||| S:1392 E:1404 ||| NN
and  ||| S:1404 E:1408 ||| CC
ADP  ||| S:1408 E:1412 ||| NNP
bleeding  ||| S:1412 E:1421 ||| NN
time  ||| S:1421 E:1426 ||| NN
( ||| S:1426 E:1427 ||| -LRB-
rho  ||| S:1427 E:1431 ||| CD
=  ||| S:1431 E:1433 ||| SYM
0.01 ||| S:1433 E:1437 ||| CD
)  ||| S:1437 E:1439 ||| -RRB-
nor  ||| S:1439 E:1443 ||| CC
to  ||| S:1443 E:1446 ||| TO
ROTEMÂ®  ||| S:1446 E:1453 ||| CD
analysis ||| S:1453 E:1461 ||| NN
.  ||| S:1461 E:1463 ||| .
Patients  ||| S:1463 E:1472 ||| NNS
with  ||| S:1472 E:1477 ||| IN
isolated  ||| S:1477 E:1486 ||| JJ
prolonged  ||| S:1486 E:1496 ||| JJ
PFA  ||| S:1496 E:1500 ||| NNS
are  ||| S:1500 E:1504 ||| VBP
mainly  ||| S:1504 E:1511 ||| RB
women  ||| S:1511 E:1517 ||| NNS
and  ||| S:1517 E:1521 ||| CC
can  ||| S:1521 E:1525 ||| MD
be  ||| S:1525 E:1528 ||| VB
affected  ||| S:1528 E:1537 ||| VBN
by  ||| S:1537 E:1540 ||| IN
all  ||| S:1540 E:1544 ||| DT
kinds  ||| S:1544 E:1550 ||| NNS
of  ||| S:1550 E:1553 ||| IN
bleedings  ||| S:1553 E:1563 ||| NN
while  ||| S:1563 E:1569 ||| IN
haematoma  ||| S:1569 E:1579 ||| NN
is  ||| S:1579 E:1582 ||| VBZ
the  ||| S:1582 E:1586 ||| DT
main  ||| S:1586 E:1591 ||| JJ
symptom ||| S:1591 E:1598 ||| NN
.  ||| S:1598 E:1600 ||| .
VWD  ||| S:1600 E:1604 ||| NNP
might  ||| S:1604 E:1610 ||| MD
not  ||| S:1610 E:1614 ||| RB
be  ||| S:1614 E:1617 ||| VB
causal ||| S:1617 E:1623 ||| NNS
.  ||| S:1623 E:1625 ||| .
